Since the US believes in Lani, is it possible for the US to start replacing expired Tamiflu with Inavir?
Lani is still not approved for use in USA. But the chance of this approval is very high.
Given the advantages of Lani over Tamiflu and Relenza and the well-selling Inavir in Japan, I believe the US will consider Lani for their stockpile before the Lani approval.
If the process of Lani trails in the US can be speeded up and manufacturing capacity built in the US soon, BTA will really profit from Lani. Of course, BTA must also negociate a good deal with DS regarding Lani ROW.
We need a more proactive and responsible BTA management to achieve a real return for our hard-earned money, which we put into the company.
Just my thoughts.
BTA Price at posting:
96.0¢ Sentiment: Hold Disclosure: Held
